Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 375

1.

The clinical implications of FDG-PET/CT differ according to histology in advanced gastric cancer.

Chon HJ, Kim C, Cho A, Kim YM, Jang SJ, Kim BO, Park CH, Hyung WJ, Ahn JB, Noh SH, Yun M, Rha SY.

Gastric Cancer. 2018 Jun 9. doi: 10.1007/s10120-018-0847-5. [Epub ahead of print]

PMID:
29948387
2.

CpG Island Methylator Phenotype and Methylation of Wnt Pathway Genes Together Predict Survival in Patients with Colorectal Cancer.

Kim SH, Park KH, Shin SJ, Lee KY, Kim TI, Kim NK, Rha SY, Ahn JB.

Yonsei Med J. 2018 Jul;59(5):588-594. doi: 10.3349/ymj.2018.59.5.588.

3.

A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy.

Chae D, Nam CM, Kim JH, Lee CK, Kim SS, Kim HS, Jung M, Cheong JH, Chung HC, Rha SY, Park K.

AAPS J. 2018 May 29;20(4):72. doi: 10.1208/s12248-018-0223-8.

PMID:
29845329
4.

MET in gastric cancer with liver metastasis: The relationship between MET amplification and Met overexpression in primary stomach tumors and liver metastasis.

Kim HS, Chon HJ, Kim H, Shin SJ, Wacheck V, Gruver AM, Kim JS, Rha SY, Chung HC.

J Surg Oncol. 2018 May 22. doi: 10.1002/jso.25097. [Epub ahead of print]

PMID:
29790169
5.

Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial.

Guo J, Jin J, Oya M, Uemura H, Takahashi S, Tatsugami K, Rha SY, Lee JL, Chung J, Lim HY, Wu HC, Chang YH, Azad A, Davis ID, Carrasco-Alfonso MJ, Nanua B, Han J, Ahmad Q, Motzer R.

J Hematol Oncol. 2018 May 22;11(1):69. doi: 10.1186/s13045-018-0617-1.

6.

'Screening audit' as a quality assurance tool in good clinical practice compliant research environments.

Park S, Nam CM, Park S, Noh YH, Ahn CR, Yu WS, Kim BK, Kim SM, Kim JS, Rha SY.

BMC Med Ethics. 2018 Apr 25;19(1):30. doi: 10.1186/s12910-018-0269-2.

7.

Landscape of Actionable Genetic Alterations Profiled from 1,071 Tumor Samples in Korean Cancer Patients.

Lee SH, Lee B, Shim JH, Lee KW, Yun JW, Kim SY, Kim TY, Kim YH, Ko YH, Chung HC, Yu CS, Lee J, Rha SY, Kim TW, Jung KH, Im SA, Moon HG, Cho S, Kang JH, Kim J, Kim SK, Ryu HS, Ha SY, Kim JI, Chung YJ, Kim C, Kim HL, Park WY, Noh DY, Park K.

Cancer Res Treat. 2018 Apr 23. doi: 10.4143/crt.2018.132. [Epub ahead of print]

8.

A phase I/Ib study of OTSGC-A24 combined peptide vaccine in advanced gastric cancer.

Sundar R, Rha SY, Yamaue H, Katsuda M, Kono K, Kim HS, Kim C, Mimura K, Kua LF, Yong WP.

BMC Cancer. 2018 Mar 27;18(1):332. doi: 10.1186/s12885-018-4234-8.

9.

Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus i.v. paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy.

Kang YK, Ryu MH, Park SH, Kim JG, Kim JW, Cho SH, Park YI, Park SR, Rha SY, Kang MJ, Cho JY, Kang SY, Roh SY, Ryoo BY, Nam BH, Jo YW, Yoon KE, Oh SC.

Ann Oncol. 2018 May 1;29(5):1220-1226. doi: 10.1093/annonc/mdy055.

PMID:
29438463
10.

Forty-nine gastric cancer cell lines with integrative genomic profiling for development of c-MET inhibitor.

Kim HJ, Kang SK, Kwon WS, Kim TS, Jeong I, Jeung HC, Kragh M, Horak ID, Chung HC, Rha SY.

Int J Cancer. 2018 Jul 1;143(1):151-159. doi: 10.1002/ijc.31304. Epub 2018 Feb 23.

PMID:
29435981
11.

Efficacy and tolerability of ramucirumab monotherapy or in combination with paclitaxel in gastric cancer patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG).

Jung M, Ryu MH, Oh DY, Kang M, Zang DY, Hwang IG, Lee KW, Kim KH, Shim BY, Song EK, Sym SJ, Han HS, Park YL, Kim JS, Lee HW, Lee MH, Koo DH, Song HS, Lee N, Yang SH, Choi DR, Hong YS, Lee KE, Maeng CH, Baek JH, Kim S, Kim YH, Rha SY, Cho JY, Kang YK.

Gastric Cancer. 2018 Feb 9. doi: 10.1007/s10120-018-0806-1. [Epub ahead of print]

PMID:
29427038
12.

Prognostic implications of polycomb proteins ezh2, suz12, and eed1 and histone modification by H3K27me3 in sarcoma.

Cho YJ, Kim SH, Kim EK, Han JW, Shin KH, Hu H, Kim KS, Choi YD, Kim S, Lee YH, Suh JS, Ahn JB, Chung HC, Noh SH, Rha SY, Jung ST, Kim HS.

BMC Cancer. 2018 Feb 7;18(1):158. doi: 10.1186/s12885-018-4066-6.

13.

S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial.

Lee CK, Jung M, Kim HS, Jung I, Shin DB, Kang SY, Zang DY, Kim KH, Lee MH, Kim BS, Lee KH, Cheong JH, Hyung WJ, Noh SH, Chung HC, Rha SY.

Cancer Res Treat. 2018 Feb 5. doi: 10.4143/crt.2018.028. [Epub ahead of print]

14.

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.

Knox JJ, Barrios CH, Kim TM, Cosgriff T, Srimuninnimit V, Pittman K, Sabbatini R, Rha SY, Flaig TW, Page RD, Beck JT, Cheung F, Yadav S, Patel P, Geoffrois L, Niolat J, Berkowitz N, Marker M, Chen D, Motzer RJ.

Ann Oncol. 2018 Jan 29. doi: 10.1093/annonc/mdx807. [Epub ahead of print] No abstract available.

PMID:
29390043
15.

Phase II study of oxaliplatin, irinotecan and S-1 therapy in patients with advanced gastric cancer: the Korean Cancer Study Group ST14-11.

Kim HS, Ryu MH, Zang DY, Park SR, Han B, Kang WK, Rha SY, Jung M, Kim JS, Kang BW, Lee KH, Rho SY, Kim JH, Kim KC, Cho JW, Choi DR, Lim H, Kang HS, Soh JS, Kim MJ, Seo J, Kang YK.

Gastric Cancer. 2018 Jan 25. doi: 10.1007/s10120-018-0794-1. [Epub ahead of print]

PMID:
29372461
16.

PTEN loss and level of HER2 amplification is associated with trastuzumab resistance and prognosis in HER2-positive gastric cancer.

Kim C, Lee CK, Chon HJ, Kim JH, Park HS, Heo SJ, Kim HJ, Kim TS, Kwon WS, Chung HC, Rha SY.

Oncotarget. 2017 Dec 9;8(69):113494-113501. doi: 10.18632/oncotarget.23054. eCollection 2017 Dec 26.

17.

Rab25 augments cancer cell invasiveness through a ╬▓1 integrin/EGFR/VEGF-A/Snail signaling axis and expression of fascin.

Jeong BY, Cho KH, Jeong KJ, Park YY, Kim JM, Rha SY, Park CG, Mills GB, Cheong JH, Lee HY.

Exp Mol Med. 2018 Jan 26;50(1):e435. doi: 10.1038/emm.2017.248.

18.

Genetic Alterations among Korean Melanoma Patients Showing Tumor Heterogeneity: A Comparison between Primary Tumors and Corresponding Metastatic Lesions.

Lee SH, Kim JE, Jang HS, Park KH, Oh BH, Shin SJ, Chung KY, Roh MR, Rha SY.

Cancer Res Treat. 2018 Jan 22. doi: 10.4143/crt.2017.535. [Epub ahead of print]

19.

Olaparib in combination with paclitaxel in patients with advanced gastric cancer who have progressed following first-line therapy (GOLD): a double-blind, randomised, placebo-controlled, phase 3 trial.

Bang YJ, Xu RH, Chin K, Lee KW, Park SH, Rha SY, Shen L, Qin S, Xu N, Im SA, Locker G, Rowe P, Shi X, Hodgson D, Liu YZ, Boku N.

Lancet Oncol. 2017 Dec;18(12):1637-1651. doi: 10.1016/S1470-2045(17)30682-4. Epub 2017 Nov 2.

PMID:
29103871
20.

Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer.

Soo Park J, Youn JC, Shim CY, Hong GR, Lee CK, Kim JH, Park HS, Heo SJ, Beom SH, Kim HS, Rha SY, Chung HC, Kang SM, Jung M.

Oncotarget. 2017 Jun 27;8(37):61837-61845. doi: 10.18632/oncotarget.18700. eCollection 2017 Sep 22.

21.

A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma.

Voss MH, Hussain A, Vogelzang N, Lee JL, Keam B, Rha SY, Vaishampayan U, Harris WB, Richey S, Randall JM, Shaffer D, Cohn A, Crowell T, Li J, Senderowicz A, Stone E, Figlin R, Motzer RJ, Haas NB, Hutson T.

Ann Oncol. 2017 Nov 1;28(11):2754-2760. doi: 10.1093/annonc/mdx493.

PMID:
28950297
22.

Changes in telomerase activity due to alternative splicing of human telomerase reverse transcriptase in colorectal cancer.

Jeung HC, Rha SY, Shin SJ, Ahn JB, Park KH, Kim TS, Kim JJ, Roh JK, Chung HC.

Oncol Lett. 2017 Aug;14(2):2385-2392. doi: 10.3892/ol.2017.6438. Epub 2017 Jun 21.

23.

A First-Time-in-Human Study of GSK2636771, a Phosphoinositide 3 Kinase Beta-Selective Inhibitor, in Patients with Advanced Solid Tumors.

Mateo J, Ganji G, Lemech C, Burris HA, Han SW, Swales K, Decordova S, DeYoung MP, Smith DA, Kalyana-Sundaram S, Wu J, Motwani M, Kumar R, Tolson JM, Rha SY, Chung HC, Eder JP, Sharma S, Bang YJ, Infante JR, Yan L, de Bono JS, Arkenau HT.

Clin Cancer Res. 2017 Oct 1;23(19):5981-5992. doi: 10.1158/1078-0432.CCR-17-0725. Epub 2017 Jun 23.

PMID:
28645941
24.

The prognostic value of volume-based parameters using 18F-FDG PET/CT in gastric cancer according to HER2 status.

Park JS, Lee N, Beom SH, Kim HS, Lee CK, Rha SY, Chung HC, Yun M, Cho A, Jung M.

Gastric Cancer. 2018 Mar;21(2):213-224. doi: 10.1007/s10120-017-0739-0. Epub 2017 Jun 22.

PMID:
28643145
25.

Pazopanib for the Treatment of Non-clear Cell Renal Cell Carcinoma: A Single-Arm, Open-Label, Multicenter, Phase II Study.

Jung KS, Lee SJ, Park SH, Lee JL, Lee SH, Lim JY, Kang JH, Lee S, Rha SY, Lee KH, Kim HY, Lim HY.

Cancer Res Treat. 2018 Apr;50(2):488-494. doi: 10.4143/crt.2016.584. Epub 2017 May 22.

26.

Integration of radiotherapy and chemotherapy for abdominal lymph node recurrence in gastric cancer.

Lee J, Yoon HI, Rha SY, Hyung WJ, Lee YC, Lim JS, Kim HS, Koom WS.

Clin Transl Oncol. 2017 Oct;19(10):1268-1275. doi: 10.1007/s12094-017-1665-7. Epub 2017 May 5.

PMID:
28477237
27.

Modulation of HAT activity by the BRCA2 N372H variation is a novel mechanism of paclitaxel resistance in breast cancer cell lines.

Kwon WS, Rha SY, Jeung HC, Kim TS, Chung HC.

Biochem Pharmacol. 2017 Aug 15;138:163-173. doi: 10.1016/j.bcp.2017.04.015. Epub 2017 Apr 18.

PMID:
28431939
28.

Prevalence and prognostic implications of psychological distress in patients with gastric cancer.

Kim GM, Kim SJ, Song SK, Kim HR, Kang BD, Noh SH, Chung HC, Kim KR, Rha SY.

BMC Cancer. 2017 Apr 20;17(1):283. doi: 10.1186/s12885-017-3260-2.

29.

The Benefit of Pro Re Nata Antiemetics Provided With Guideline-Consistent Antiemetics in Delayed Nausea Control.

Rha SY, Sohn J, Kim GM, Kim HR, Lee J.

Cancer Nurs. 2018 Mar/Apr;41(2):E49-E57. doi: 10.1097/NCC.0000000000000484.

PMID:
28418944
30.

Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer.

Kim HS, Lee H, Shin SJ, Beom SH, Jung M, Bae S, Lee EY, Park KH, Choi YY, Son T, Kim HI, Cheong JH, Hyung WJ, Park JC, Shin SK, Lee SK, Lee YC, Koom WS, Lim JS, Chung HC, Noh SH, Rha SY, Kim H, Paik S.

Oncotarget. 2017 Jun 13;8(24):38389-38398. doi: 10.18632/oncotarget.16409.

31.

Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab.

Lee CK, Kim SS, Park S, Kim C, Heo SJ, Lim JS, Kim H, Kim HS, Rha SY, Chung HC, Park S, Jung M.

Oncotarget. 2017 May 9;8(19):31169-31179. doi: 10.18632/oncotarget.16099.

32.

Characterizing the outcomes of metastatic papillary renal cell carcinoma.

Connor Wells J, Donskov F, Fraccon AP, Pasini F, Bjarnason GA, Beuselinck B, Knox JJ, Rha SY, Agarwal N, Bowman IA, Lee JL, Pal SK, Srinivas S, Scott Ernst D, Vaishampayan UN, Wood LA, Simpson R, De Velasco G, Choueiri TK, Heng DYC.

Cancer Med. 2017 May;6(5):902-909. doi: 10.1002/cam4.1048. Epub 2017 Apr 16.

33.

Erratum to: Symptom clusters during palliative chemotherapy and their influence on functioning and quality of life.

Rha SY, Lee J.

Support Care Cancer. 2017 Aug;25(8):2671-2672. doi: 10.1007/s00520-017-3705-9. No abstract available.

PMID:
28401313
34.

A phase 1, open label, dose escalation study to investigate the safety, tolerability, and pharmacokinetics of MG1102 (apolipoprotein(a) Kringle V) in patients with solid tumors.

Kim GM, Reid T, Shin SJ, Rha SY, Ahn JB, Lee SS, Chung HC.

Invest New Drugs. 2017 Dec;35(6):773-781. doi: 10.1007/s10637-017-0460-1. Epub 2017 Mar 28.

PMID:
28353123
35.

Final overall survival analysis for the phase II RECORD-3 study of first-line everolimus followed by sunitinib versus first-line sunitinib followed by everolimus in metastatic RCC.

Knox JJ, Barrios CH, Kim TM, Cosgriff T, Srimuninnimit V, Pittman K, Sabbatini R, Rha SY, Flaig TW, Page RD, Beck JT, Cheung F, Yadav S, Patel P, Geoffrois L, Niolat J, Berkowitz N, Marker M, Chen D, Motzer RJ.

Ann Oncol. 2017 Jun 1;28(6):1339-1345. doi: 10.1093/annonc/mdx075.

36.

Epigenomic Promoter Alterations Amplify Gene Isoform and Immunogenic Diversity in Gastric Adenocarcinoma.

Qamra A, Xing M, Padmanabhan N, Kwok JJT, Zhang S, Xu C, Leong YS, Lee Lim AP, Tang Q, Ooi WF, Suling Lin J, Nandi T, Yao X, Ong X, Lee M, Tay ST, Keng ATL, Gondo Santoso E, Ng CCY, Ng A, Jusakul A, Smoot D, Ashktorab H, Rha SY, Yeoh KG, Peng Yong W, Chow PKH, Chan WH, Ong HS, Soo KC, Kim KM, Wong WK, Rozen SG, Teh BT, Kappei D, Lee J, Connolly J, Tan P.

Cancer Discov. 2017 Jun;7(6):630-651. doi: 10.1158/2159-8290.CD-16-1022. Epub 2017 Mar 20.

37.
38.

Discontinuing VEGF-targeted Therapy for Progression Versus Toxicity Affects Outcomes of Second-line Therapies in Metastatic Renal Cell Carcinoma.

De Velasco G, Xie W, Donskov F, Albiges L, Beuselinck B, Srinivas S, Agarwal N, Lee JL, Brugarolas J, Wood LA, Rha SY, Kollmannsberger C, North S, Kanesvaran R, Rini BI, Broom R, Yamamoto H, Kaymakcalan MD, Heng DYC, Choueiri TK.

Clin Genitourin Cancer. 2017 Jun;15(3):403-410.e2. doi: 10.1016/j.clgc.2017.01.005. Epub 2017 Jan 12.

PMID:
28254206
39.

Locoregional relapse after gastrectomy with D2 lymphadenectomy for gastric cancer.

Chang JS, Kim KH, Yoon HI, Hyung WJ, Rha SY, Kim HS, Lee YC, Lim JS, Noh SH, Koom WS.

Br J Surg. 2017 Jun;104(7):877-884. doi: 10.1002/bjs.10502. Epub 2017 Feb 28.

PMID:
28245053
40.

Different subtypes of epithelioid sarcoma and their clinical implication: long-term multi-institutional experience with a rare sarcoma.

Kim C, Yoo KH, Kim MH, Chon HJ, Lee SI, Lee HJ, Koh S, Lee HY, Lee HR, Kim KS, Choi YD, Rha SY, Lee SJ, Kim HS.

APMIS. 2017 Mar;125(3):223-229. doi: 10.1111/apm.12656.

PMID:
28233450
41.

Telomerase reverse transcriptase (TERT) promoter mutations in Korean melanoma patients.

Roh MR, Park KH, Chung KY, Shin SJ, Rha SY, Tsao H.

Am J Cancer Res. 2017 Jan 1;7(1):134-138. eCollection 2017.

42.

Symptom clusters during palliative chemotherapy and their influence on functioning and quality of life.

Rha SY, Lee J.

Support Care Cancer. 2017 May;25(5):1519-1527. doi: 10.1007/s00520-016-3545-z. Epub 2016 Dec 28. Erratum in: Support Care Cancer. 2017 Aug;25(8):2671-2672.

PMID:
28032218
43.

ABCB1 2677G>T/A variant enhances chemosensitivity to anti-cancer agents acting on microtubule dynamics through LAMP1 inhibition.

Kwon WS, Rha SY, Jeung HC, Ahn JB, Jung JJ, Ki DH, Kim TS, Chung HC.

Biochem Pharmacol. 2017 Jan 1;123:73-84. doi: 10.1016/j.bcp.2016.11.005. Epub 2016 Nov 7.

PMID:
27832934
44.

Recursive partition analysis of peritoneal and systemic recurrence in patients with gastric cancer who underwent D2 gastrectomy: Implications for neoadjuvant therapy consideration.

Chang JS, Kim KH, Keum KC, Noh SH, Lim JS, Kim HS, Rha SY, Lee YC, Hyung WJ, Koom WS.

J Surg Oncol. 2016 Dec;114(7):859-864. doi: 10.1002/jso.24405. Epub 2016 Aug 11.

PMID:
27511744
45.

Receptor tyrosine kinase amplified gastric cancer: Clinicopathologic characteristics and proposed screening algorithm.

Park CK, Park JS, Kim HS, Rha SY, Hyung WJ, Cheong JH, Noh SH, Lee SK, Lee YC, Huh YM, Kim H.

Oncotarget. 2016 Nov 1;7(44):72099-72112. doi: 10.18632/oncotarget.12291.

46.

Efficacy and Toxicity of Mammalian Target Rapamycin Inhibitors in Patients with Metastatic Renal Cell Carcinoma with Renal Insufficiency: The Korean Cancer Study Group GU 14-08.

Kim KH, Kim JH, Lee JY, Kim HS, Heo SJ, Kim JH, Kim HY, Rha SY.

Cancer Res Treat. 2016 Oct;48(4):1286-1292. Epub 2016 Feb 12.

47.

PRL3-zumab, a first-in-class humanized antibody for cancer therapy.

Thura M, Al-Aidaroos AQ, Yong WP, Kono K, Gupta A, Lin YB, Mimura K, Thiery JP, Goh BC, Tan P, Soo R, Hong CW, Wang L, Lin SJ, Chen E, Rha SY, Chung HC, Li J, Nandi S, Yuen HF, Zhang SD, Guan YK, So J, Zeng Q.

JCI Insight. 2016 Jun 16;1(9):e87607.

48.

Epigenomic profiling of primary gastric adenocarcinoma reveals super-enhancer heterogeneity.

Ooi WF, Xing M, Xu C, Yao X, Ramlee MK, Lim MC, Cao F, Lim K, Babu D, Poon LF, Lin Suling J, Qamra A, Irwanto A, Qu Zhengzhong J, Nandi T, Lee-Lim AP, Chan YS, Tay ST, Lee MH, Davies JO, Wong WK, Soo KC, Chan WH, Ong HS, Chow P, Wong CY, Rha SY, Liu J, Hillmer AM, Hughes JR, Rozen S, Teh BT, Fullwood MJ, Li S, Tan P.

Nat Commun. 2016 Sep 28;7:12983. doi: 10.1038/ncomms12983.

49.

A novel TP53-KPNA3 translocation defines a de novo treatment-resistant clone in osteosarcoma.

Chen KS, Kwon WS, Kim J, Heo SJ, Kim HS, Kim HK, Kim SH, Lee WS, Chung HC, Rha SY, Hwang TH.

Cold Spring Harb Mol Case Stud. 2016 Sep;2(5):a000992. doi: 10.1101/mcs.a000992.

50.

Body Mass Index and Metastatic Renal Cell Carcinoma: Clinical and Biological Correlations.

Albiges L, Hakimi AA, Xie W, McKay RR, Simantov R, Lin X, Lee JL, Rini BI, Srinivas S, Bjarnason GA, Ernst S, Wood LA, Vaishamayan UN, Rha SY, Agarwal N, Yuasa T, Pal SK, Bamias A, Zabor EC, Skanderup AJ, Furberg H, Fay AP, de Velasco G, Preston MA, Wilson KM, Cho E, McDermott DF, Signoretti S, Heng DY, Choueiri TK.

J Clin Oncol. 2016 Sep 6. pii: JCO667311. [Epub ahead of print]

Supplemental Content

Support Center